{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:23:11Z","timestamp":1794864191309,"version":"4.9.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.modpat.2026.101094","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:06:27Z","timestamp":1791216387000},"page":"101094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["FGFR2\/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival"],"prefix":"10.1016","volume":"39","author":[{"given":"Wen-Yu","family":"Hsiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Angara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3695-8192","authenticated-orcid":false,"given":"Haider A.","family":"Mejbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.modpat.2026.101094_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"suppl 1","key":"10.1016\/j.modpat.2026.101094_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological, and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.modpat.2026.101094_bib3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/jnci\/djj234","article-title":"Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States","volume":"98","author":"Welzel","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.modpat.2026.101094_bib4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.dld.2009.10.009","article-title":"Descriptive epidemiology of cholangiocarcinoma in Italy","volume":"42","author":"Alvaro","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.modpat.2026.101094_bib5","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3748\/wjg.v18.i5.458","article-title":"Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia","volume":"18","author":"Yusoff","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101094_bib6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101094_bib7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.modpat.2026.101094_bib8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/modpathol.2013.241","article-title":"Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features","volume":"27","author":"Liau","year":"2014","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101094_bib9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.hpb.2018.07.021","article-title":"Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma","volume":"21","author":"Akita","year":"2019","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.modpat.2026.101094_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.humpath.2022.06.001","article-title":"Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities","volume":"132","author":"Zen","year":"2023","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101094_bib11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00428-025-04067-9","article-title":"FGFR2 fusion\/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA\/RNA-based NGS and FISH","volume":"487","author":"Zhang","year":"2025","journal-title":"Virchows Arch"},{"issue":"9","key":"10.1016\/j.modpat.2026.101094_bib12","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.modpat.2026.101094_bib13","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.modpat.2026.101094_bib14","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.modpat.2026.101094_bib15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.modpat.2026.101094_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.modpat.2026.101094_bib17","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.dld.2024.04.025","article-title":"Intrahepatic cholangiocarcinoma with FGFR alterations: a series of Chinese cases with an emphasis on their clinicopathologic and genetic features","volume":"56","author":"Zhou","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.modpat.2026.101094_bib18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.modpat.2026.101094_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101094_bib20","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.modpat.2026.101094_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41419-021-03548-4","article-title":"Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas","volume":"12","author":"Pu","year":"2021","journal-title":"Cell Death Dis"},{"issue":"10","key":"10.1016\/j.modpat.2026.101094_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101168","article-title":"Targeted genomic profiling revealed a unique clinical phenotype in intrahepatic cholangiocarcinoma with fibroblast growth factor receptor rearrangement","volume":"14","author":"Zhu","year":"2021","journal-title":"Transl Oncol"},{"issue":"9","key":"10.1016\/j.modpat.2026.101094_bib23","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41416-022-01932-1","article-title":"Precision oncology for intrahepatic cholangiocarcinoma in clinical practice","volume":"127","author":"Tomczak","year":"2022","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2026.101094_bib24","first-page":"1355","article-title":"Molecular detection of FGFR2 rearrangements in resected intrahepatic cholangiocarcinomas: FISH could be an ideal method in patients with histological small duct subtype","volume":"11","author":"Zou","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.modpat.2026.101094_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.modpat.2026.101094_bib26","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.modpat.2026.101094_bib27","series-title":"Digestive System Tumours","year":"2019"},{"key":"10.1016\/j.modpat.2026.101094_bib28","author":"Amin","year":"2017"},{"key":"10.1016\/j.modpat.2026.101094_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101094_bib30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1200\/JOP.2016.018929","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline summary from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"13","author":"Bartley","year":"2017","journal-title":"J Oncol Pract"},{"issue":"7","key":"10.1016\/j.modpat.2026.101094_bib31","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jgh.12916","article-title":"Role of the fibroblast growth factor receptor axis in cholangiocarcinoma","volume":"30","author":"Ang","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"issue":"18","key":"10.1016\/j.modpat.2026.101094_bib32","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.3390\/ijms21186856","article-title":"FGFR fusions in cancer: from diagnostic approaches to therapeutic intervention","volume":"21","author":"De Luca","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.modpat.2026.101094_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12876-016-0527-z","article-title":"Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database","volume":"16","author":"Yao","year":"2016","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101094_bib34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.modpat.2026.101094_bib35","doi-asserted-by":"crossref","first-page":"e1734","DOI":"10.1093\/oncolo\/oyae170","article-title":"FGFR2 fusion\/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma","volume":"29","author":"Liu","year":"2024","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.modpat.2026.101094_bib36","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11523-022-00906-w","article-title":"Effect of FGFR2 alterations on overall and progression-free survival in patients receiving systemic therapy for intrahepatic cholangiocarcinoma","volume":"17","author":"Abou-Alfa","year":"2022","journal-title":"Target Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101094_bib37","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MOG.0000000000000171","article-title":"Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma","volume":"31","author":"Borad","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.modpat.2026.101094_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1527484","article-title":"Case report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A\/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion","volume":"15","author":"Ballin","year":"2025","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101094_bib39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.modpat.2026.101094_bib40","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2026.101094_bib41","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/2159-8290.CD-24-0417","article-title":"Pan-cancer analysis of oncogenic MET fusions reveals distinct pathogenomic subsets with differential sensitivity to MET-targeted therapy","volume":"15","author":"Febres-Aldana","year":"2025","journal-title":"Cancer Discov"},{"issue":"13_Supplement","key":"10.1016\/j.modpat.2026.101094_bib42","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-935","article-title":"Abstract 935: preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions","volume":"81","author":"Odintsov","year":"2021","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.modpat.2026.101094_bib43","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/PAS.0000000000000670","article-title":"Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma","volume":"40","author":"Hayashi","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101094_bib44","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.modpat.2026.101094_bib45","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.modpat.2026.101094_bib46","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat Commun"},{"issue":"50","key":"10.1016\/j.modpat.2026.101094_bib47","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.1038\/sj.onc.1210529","article-title":"Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes","volume":"26","author":"Pollock","year":"2007","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.modpat.2026.101094_bib48","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1172\/JCI62644","article-title":"p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice","volume":"122","author":"Wang","year":"2012","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.modpat.2026.101094_bib49","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/2159-8290.CD-20-1669","article-title":"FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma","volume":"11","author":"Cleary","year":"2021","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.modpat.2026.101094_bib50","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/sj.onc.1200983","article-title":"Activation of FGF receptors by mutations in the transmembrane domain","volume":"14","author":"Li","year":"1997","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.modpat.2026.101094_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035826","article-title":"Receptor tyrosine kinases activate canonical WNT\/beta-catenin signaling via the MAP kinase\/LRP6 pathway and direct beta-catenin phosphorylation","volume":"7","author":"Krejci","year":"2012","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.modpat.2026.101094_bib52","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.3390\/cells11233929","article-title":"FGFR inhibitors in cholangiocarcinoma: a novel yet primary approach: where do we stand now and where to head next in targeting this axis?","volume":"11","author":"Chmiel","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.modpat.2026.101094_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107968","article-title":"FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma","volume":"221","author":"Song","year":"2025","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.modpat.2026.101094_bib54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.modpat.2026.101094_bib55","doi-asserted-by":"crossref","first-page":"403","DOI":"10.6004\/jnccn.2025.0042","article-title":"Biliary tract cancers, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Benson","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.modpat.2026.101094_bib56","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/liv.15984","article-title":"Prognostic value of FGFR2 alterations in patients with iCCA undergoing surgery or systemic treatments: a meta-analysis","volume":"44","author":"Niu","year":"2024","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.modpat.2026.101094_bib57","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.hpb.2022.05.1341","article-title":"Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection","volume":"24","author":"Buckarma","year":"2022","journal-title":"HPB (Oxford)"},{"issue":"1","key":"10.1016\/j.modpat.2026.101094_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17175-7","article-title":"CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma","volume":"7","author":"Loosen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.modpat.2026.101094_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.844800","article-title":"TP53\/KRAS co-mutations create divergent prognosis signatures in intrahepatic cholangiocarcinoma","volume":"13","author":"Guo","year":"2022","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.modpat.2026.101094_bib60","article-title":"Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis","volume":"18","author":"Peng","year":"2023","journal-title":"Open Life Sci"},{"issue":"6","key":"10.1016\/j.modpat.2026.101094_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO Open"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:08:50Z","timestamp":1794863330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226001377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0893395226001377"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101094","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR2\/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101094"}}